Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared
to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)